FEATURED CONTENT

• What Controlled Immune Challenges Reveal Before Patient Studies Begin

  Controlled immune challenges can reveal target engagement and pharmacology before efficacy is measurable, supporting earlier and more informed development decisions.

• Making Early Decisions In Psychiatric Drug Development

  Quantitative PD measures provide objective evidence of target engagement, support dose selection, strengthen early go/no-go decisions, and help reduce development risk in psychiatric

• How NeuroKit® Helps Avoid False Negatives in Early CNS Development

  Detecting subtle CNS effects early can reduce false negatives. Sensitive assessments strengthen confidence in pharmacodynamic signals and dose selection.

   

• EU Clinical Trial Regulation Timelines: Shorter Than Many Expect

  The EU CTR rewards early planning. Strong documentation, regulatory readiness, and aligned partners can help accelerate approvals and reduce delays.

• Building Recruitment Into Early-Phase Trial Design

  Successful recruitment starts with smart study design. Early recruitment insight improves feasibility, supports realistic timelines, and reduces enrollment risk.

• Balancing Patient Convenience And Signal Integrity In CNS Trials

  Early CNS trials depend on precise data. Hybrid approaches can reduce participant burden, but critical assessments often require controlled environments to preserve signal integrity.

• A Sponsor's Guide To Evaluating CRO Data Governance

  Evaluate CRO data governance with a risk-based framework that strengthens data quality, traceability, compliance, and regulatory readiness.

• Interpreting Early Inflammation Signals: What Early Human Data Tells Us

  Early inflammatory signals can mislead without context. Benchmarked human challenge models reveal true biological activity, guiding decisions on mechanism, dosing, and clinical development.

• Why Benchmarking Inflammatory Models Matters: What Early Human Data Tells Us

  Benchmarking immune challenge models clarifies early pharmacodynamic signals, helping teams distinguish true target engagement from variability, prioritize endpoints, and make confident decisions.

• Expression Of Key Immunology Drug Targets In Human Inflammatory Challenge Models

  Human challenge models reveal immune pathway behavior in controlled settings, linking early research to outcomes and helping confirm target engagement, refine dosing, and reduce development uncertainty.

• How Pharmacometrics Informs Dose Selection And Biomarker Decisions

  Quantitative modeling guides early dose and biomarker insights, reducing uncertainty, improving study design, and enabling faster, more confident decisions from first trials to clinical progress.

• Why Early Clinical Development Is Shifting Toward Decision-Enabling Study Designs

  Early clinical research is shifting to decision-focused designs, using biomarkers, functional endpoints, and targeted populations to reduce uncertainty and enable clearer progression.

• Why AI Matters In Early Phase Clinical Trials

  AI speeds early‑phase development by streamlining data review, enabling structured queries, accelerating PK/PD work, and revealing biomarker patterns — boosting efficiency with expert oversight.

• Accelerating Parkinson's Disease Clinical Research Through Recruitment Capabilities

  Centralized PD trials cut variability, speed enrollment, and enable genetic stratification, delivering high‑quality data and faster progress from early‑phase research to late‑stage development.

• Navigating The Enrollment Bottleneck In Early Oncology Trials

  Slow oncology trial enrollment raises costs and delays progress. AI prescreening, patient-focused engagement, and early pharmacology studies help accelerate recruitment and optimize trial design.

• 6 Key Implications Of EU Clinical Trials Regulation

  Centralized submissions, greater transparency, and stronger patient protections reshape EU clinical trials, impacting timelines, costs, and strategies for sponsors and CROs.

• Psychiatric Drug Development Renaissance: With Familiar Risks

  Emerging psychiatric therapies bring hope, but progress is fragile. Biomarker-driven, mechanism-first approaches help overcome biological, regulatory, and commercial barriers.

• Trailblazing Clinical Drug Development In Dermatology

  AI, imaging, and biomarkers are transforming trials, reducing subjectivity and improving sensitivity while enabling decentralized designs, faster timelines, and more precise insights.

• Year-In-Review: Clinical Research Today And Tomorrow

  As the industry prepares for 2026, sponsors and investors alike face a pivotal moment — one that demands a more deliberate, insight-driven approach to early clinical development.

• The Impact Of Expert PK/PD Modeling In Psychedelic Research

  Model-informed development that integrates preclinical and literature-based data is enabling smarter predictions of exposure and safety, transforming psychedelic research and advancing clinical innovation.